Veru (NASDAQ:VERU - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $3.00 target price on the stock. HC Wainwright's price target would suggest a potential upside of 125.56% from the stock's current price.
VERU has been the subject of a number of other research reports. Raymond James began coverage on Veru in a research report on Thursday, March 28th. They issued an "outperform" rating and a $3.00 price objective for the company. Oppenheimer reiterated an "outperform" rating and set a $5.00 price target (down previously from $7.00) on shares of Veru in a research note on Monday, April 15th.
View Our Latest Stock Report on Veru
Veru Price Performance
NASDAQ:VERU remained flat at $1.33 during trading hours on Monday. 1,083,317 shares of the company traded hands, compared to its average volume of 2,380,887. Veru has a 1 year low of $0.36 and a 1 year high of $1.92. The stock's fifty day moving average price is $1.03 and its 200-day moving average price is $0.82. The company has a market capitalization of $194.69 million, a PE ratio of -3.91 and a beta of -0.47.
Veru (NASDAQ:VERU - Get Free Report) last announced its quarterly earnings data on Monday, April 1st. The company reported ($0.09) EPS for the quarter. Veru had a negative net margin of 265.27% and a negative return on equity of 130.13%. The company had revenue of $2.14 million for the quarter. On average, analysts expect that Veru will post -0.26 EPS for the current year.
Institutional Investors Weigh In On Veru
Large investors have recently modified their holdings of the stock. Choreo LLC acquired a new stake in Veru in the 1st quarter valued at $64,000. 180 Wealth Advisors LLC acquired a new stake in shares of Veru in the 1st quarter valued at $120,000. Perceptive Advisors LLC grew its holdings in shares of Veru by 412.4% in the 4th quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company's stock worth $4,021,000 after purchasing an additional 4,494,821 shares during the last quarter. Octagon Capital Advisors LP acquired a new stake in shares of Veru during the 4th quarter worth about $2,736,000. Finally, ADAR1 Capital Management LLC bought a new position in Veru during the 4th quarter valued at about $360,000. 47.16% of the stock is currently owned by institutional investors.
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
